cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Neoleukin Therapeutics Inc
9 own
14 watching
Current Price
$0
$0
(-0.01%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
33.83M
52-Week High
52-Week High
1.3408
52-Week Low
52-Week Low
0.375
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization33.83M
icon52-Week High1.3408
icon52-Week Low0.375
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Neoleukin Therapeutics Inc do?
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Read More
How much money does Neoleukin Therapeutics Inc make?
News & Events about Neoleukin Therapeutics Inc.
Globe Newswire
6 months ago
Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cellsSEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics...
Ticker Report
6 months ago
HC Wainwright cut shares of Neoleukin Therapeutics (NASDAQ:NLTX Get Rating) from a buy rating to a neutral rating in a research report report published on Wednesday morning, The Fly reports. HC Wainwright also issued estimates for Neoleukin Therapeutics Q2 2023 earnings at ($0.17) EPS...
Globe Newswire
7 months ago
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming American Society of Hematology (ASH...
Zolmax
1 year ago
Zacks Investment Research cut shares of Neoleukin Therapeutics (NASDAQ:NLTX Get Rating) from a buy rating to a hold rating in a research report report published on Friday morning, Zacks.com reports. According to Zacks, Neoleukin Therapeutics Inc. is a biopharmaceutical company. It is engaged in ...
Globe Newswire
1 year ago
- NL-201 demonstrates antitumor activity in preclinical B-cell lymphoma models - - NL-201 synergizes with radiation therapy to generate potent, antitumor immunity - SEATTLE, April 13, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company ...
Frequently Asked Questions
Frequently Asked Questions
What is Neoleukin Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Neoleukin Therapeutics Inc shares?
plus_minus_icon
How can I buy Neoleukin Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Neoleukin Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Neoleukin Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Neoleukin Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Neoleukin Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Neoleukin Therapeutics Inc?
plus_minus_icon
What percentage is Neoleukin Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Neoleukin Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0
(-0.01%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.11
$0.01 (1.15 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$1.46
$-0.01 (-0.52 %)
Surface Oncology Inc
Surface Oncology Inc
$0.78
$0.00 (0.41 %)
Magenta Therapeutics Inc
Magenta Therapeutics Inc
$0.73
$0.01 (1.47 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.11
$0.01 (1.15 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$1.46
$-0.01 (-0.52 %)
Surface Oncology Inc
Surface Oncology Inc
$0.78
$0.00 (0.41 %)
Magenta Therapeutics Inc
Magenta Therapeutics Inc
$0.73
$0.01 (1.47 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00